Inter-Cohort Validation of SuStaIn Model for Alzheimer's Disease

被引:17
作者
Archetti, Damiano [1 ]
Young, Alexandra L. [2 ,3 ]
Oxtoby, Neil P. [3 ]
Ferreira, Daniel [4 ,5 ]
Martensson, Gustav [4 ]
Westman, Eric [4 ]
Alexander, Daniel C. [3 ]
Frisoni, Giovanni B. [6 ,7 ,8 ,9 ]
Redolfi, Alberto [1 ]
机构
[1] IRCCS Ist Ctr San Giovanni Dio Fatebenefratell, Lab Neuroinformat, Brescia, Italy
[2] Kings Coll London, Inst Psychiat, Dept Neuroimaging Psychol & Neurosci, London, England
[3] UCL Ctr Med Image Comp, Dept Comp Sci, London, England
[4] Karolinska Inst, Div Clin Geriatr, Dept Neurobiol Care Sci & Soc, Ctr Alzheimer Res, Stockholm, Sweden
[5] Mayo Clin, Dept Radiol, Rochester, MN USA
[6] Univ Hosp, Memory Clin, Geneva, Switzerland
[7] Univ Hosp, LANVIE Lab Neuroimaging Aging, Geneva, Switzerland
[8] Univ Geneva, Geneva, Switzerland
[9] IRCCS Ist Ctr San Giovanni Dio Fatebenefratell, Lab Alzheimers Neuroimaging & Epidemiol LANE, Brescia, Italy
来源
FRONTIERS IN BIG DATA | 2021年 / 4卷
基金
加拿大健康研究院; 美国国家卫生研究院; 欧盟地平线“2020”;
关键词
alzheiemer's disease; patient subtyping; patient staging; SuStain model; inter-cohort validation; MENTAL-STATE-EXAMINATION; INTRAOBSERVER REPRODUCIBILITY; NEURODEGENERATIVE DISEASES; HYPOTHETICAL MODEL; BIOMARKER CHANGES; CEREBRAL ATROPHY; DEFINED SUBTYPES; STRUCTURAL MRI; DEMENTIA; HETEROGENEITY;
D O I
10.3389/fdata.2021.661110
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disorder which spans several years from preclinical manifestations to dementia. In recent years, interest in the application of machine learning (ML) algorithms to personalized medicine has grown considerably, and a major challenge that such models face is the transferability from the research settings to clinical practice. The objective of this work was to demonstrate the transferability of the Subtype and Stage Inference (SuStaIn) model from well-characterized research data set, employed as training set, to independent less-structured and heterogeneous test sets representative of the clinical setting. The training set was composed of MRI data of 1043 subjects from the Alzheimer's disease Neuroimaging Initiative (ADNI), and the test set was composed of data from 767 subjects from OASIS, Pharma-Cog, and ViTA clinical datasets. Both sets included subjects covering the entire spectrum of AD, and for both sets volumes of relevant brain regions were derived from T1-3D MRI scans processed with Freesurfer v5.3 cross-sectional stream. In order to assess the predictive value of the model, subpopulations of subjects with stable mild cognitive impairment (MCI) and MCIs that progressed to AD dementia (pMCI) were identified in both sets. SuStaIn identified three disease subtypes, of which the most prevalent corresponded to the typical atrophy pattern of AD. The other SuStaIn subtypes exhibited similarities with the previously defined hippocampal sparing and limbic predominant atrophy patterns of AD. Subject subtyping proved to be consistent in time for all cohorts and the staging provided by the model was correlated with cognitive performance. Classification of subjects on the basis of a combination of SuStaIn subtype and stage, mini mental state examination and amyloid-beta(1-42) cerebrospinal fluid concentration was proven to predict conversion from MCI to AD dementia on par with other novel statistical algorithms, with ROC curves that were not statistically different for the training and test sets and with area under curve respectively equal to 0.77 and 0.76. This study proves the transferability of a SuStaIn model for AD from research data to less-structured clinical cohorts, and indicates transferability to the clinical setting.
引用
收藏
页数:13
相关论文
共 63 条
  • [1] Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans
    Aisen, Paul S.
    Petersen, Ronald C.
    Donohue, Michael C.
    Gamst, Anthony
    Raman, Rema
    Thomas, Ronald G.
    Walter, Sarah
    Trojanowski, John Q.
    Shaw, Leslie M.
    Beckett, Laurel A.
    Jack, Clifford R., Jr.
    Jagust, William
    Toga, Arthur W.
    Saykin, Andrew J.
    Morris, John C.
    Green, Robert C.
    Weiner, Michael W.
    [J]. ALZHEIMERS & DEMENTIA, 2010, 6 (03) : 239 - 246
  • [2] Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease
    Archetti, Damiano
    Ingala, Silvia
    Venkatraghavan, Vikram
    Wottschel, Viktor
    Young, Alexandra L.
    Bellio, Maura
    Bron, Esther E.
    Klein, Stefan
    Barkhof, Frederik
    Alexander, Daniel C.
    Oxtoby, Neil P.
    Frisonif, Giovanni B.
    Redolfi, Alberto
    [J]. NEUROIMAGE-CLINICAL, 2019, 24
  • [3] NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES
    BRAAK, H
    BRAAK, E
    [J]. ACTA NEUROPATHOLOGICA, 1991, 82 (04) : 239 - 259
  • [4] Enzyme-linked immunosorbent assay (Reprinted from Immunochemistry, pg 759-803, 1994)
    Butler, JE
    [J]. JOURNAL OF IMMUNOASSAY, 2000, 21 (2-3): : 165 - 209
  • [5] Tackling dementia globally: the Global Dementia Prevention Program (GloDePP) collaboration
    Chan, Kit Yee
    Adeloye, Davies
    Asante, Kwaku Poku
    Calia, Clara
    Campbell, Harry
    Danso, Samuel O.
    Juvekar, Sanjay
    Luz, Saturnino
    Mohan, Devi
    Muniz-Terrera, Graciela
    Nitrini, Ricardo
    Noroozian, Maryam
    Nulkar, Amit
    Nyame, Solomon
    Paralikar, Vasudeo
    Rodriguez, Mario A. Parra
    Poon, Adrienne N.
    Reidpath, Daniel D.
    Rudan, Igor
    Stephan, Blossom C. M.
    Su, TinTin
    Wang, Huali
    Watermeyer, Tam
    Wilkinson, Heather
    Yassuda, Monica Sanches
    Yu, Xin
    Ritchie, Craig
    [J]. JOURNAL OF GLOBAL HEALTH, 2019, 9 (02)
  • [6] The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group
    Costa, Alberto
    Bak, Thomas
    Caffarra, Paolo
    Caltagirone, Carlo
    Ceccaldi, Mathieu
    Collette, Fabienne
    Crutch, Sebastian
    Della Sala, Sergio
    Demonet, Jean Francois
    Dubois, Bruno
    Duzel, Emrah
    Nestor, Peter
    Papageorgiou, Sokratis G.
    Salmon, Eric
    Sikkes, Sietske
    Tiraboschi, Pietro
    van der Flier, Wiesje M.
    Visser, Pieter Jelle
    Cappa, Stefano F.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [7] ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration
    Cousins, Katheryn A. Q.
    Irwin, David J.
    Wolk, David A.
    Lee, Edward B.
    Shaw, Leslie M. J.
    Trojanowski, John Q.
    Re, Fulvio
    Gibbons, Garrett S.
    Grossman, Murray
    Phillips, Jeffrey S.
    [J]. BRAIN, 2020, 143 : 2295 - 2311
  • [8] Delaby C., 2020, ALZHEIMERS DEMEN, V16, DOI [10.1002/alz.047209, DOI 10.1002/ALZ.047209]
  • [9] COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH
    DELONG, ER
    DELONG, DM
    CLARKEPEARSON, DI
    [J]. BIOMETRICS, 1988, 44 (03) : 837 - 845
  • [10] Progression of regional grey matter atrophy in multiple sclerosis
    Eshaghi, Arman
    Marinescu, Razvan V.
    Young, Alexandra L.
    Firth, Nicholas C.
    Prados, Ferran
    Cardoso, M. Jorge
    Tur, Carmen
    De Angelis, Floriana
    Cawley, Niamh
    Brownlee, Wallace J.
    De Stefano, Nicola
    Stromillo, M. Laura
    Battaglini, Marco
    Ruggieri, Serena
    Gasperini, Claudio
    Filippi, Massimo
    Rocca, Maria A.
    Rovira, Alex
    Sastre-Garriga, Jaume
    Geurts, Jeroen J. G.
    Vrenken, Hugo
    Wottschel, Viktor
    Leurs, Cyra E.
    Uitdehaag, Bernard
    Pirpamer, Lukas
    Enzinger, Christian
    Ourselin, Sebastien
    Wheeler-Kingshott, Claudia A. Gandini
    Chard, Declan
    Thompson, Alan J.
    Barkhof, Frederik
    Alexander, Daniel C.
    Ciccarelli, Olga
    [J]. BRAIN, 2018, 141 : 1665 - 1677